Soleus Capital Management, L.P. Chinook Therapeutics, Inc. Transaction History

Soleus Capital Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$17.51 - $23.37 $175,100 - $233,700	-10,000 Reduced 11.36%	78,000 $1.53 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $1.11 Million - $1.65 Million	88,000 New	88,000 $1.54 Million
Q1 2022 May 16, 2022	SELL	$12.02 - $16.69 $3.59 Million - $4.99 Million	-298,700 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $3.19 Million - $5.03 Million	298,700 New	298,700 $4.87 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.